New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse [Yahoo! Finance]
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The ‘Personalis NeXT Personal® liquid biopsy' test uses whole genome sequencing to identify up to 1,800 mutations in a patient's tumour DNA that can identify recurrence of the patient's cancer from a blood sample The median lead time from detection of disease to clinical relapse (shown on imaging) was 15 months – over three months earlier than other types of ctDNA tests Research results pave the way for a new follow-up strategy for treating recurrent breast cancer LONDON, June 02, 2024 BUSINESS WIRE )--A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The Institute of Cancer Research, London, used an ultra-sensitive liquid biopsy to detect the presence of tiny amounts of cancer DNA left in the body following treatment for early breast cancer. The findings, presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday 2 June
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.MarketBeat
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference [Yahoo! Finance]Yahoo! Finance
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution ConferenceBusiness Wire
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call [Yahoo! Finance]Yahoo! Finance
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference CallBusiness Wire
PSNL
Earnings
- 5/8/24 - Beat
PSNL
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- PSNL's page on the SEC website